|
Volumn 21, Issue 2, 2010, Pages 430-
|
Concomitant medications in cancer patients: Should we be more active in their management?
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTIHYPERTENSIVE AGENT;
BETA ADRENERGIC RECEPTOR BLOCKING AGENT;
WARFARIN;
ANTINEOPLASTIC AGENT;
BLEEDING;
CANCER DIAGNOSIS;
CANCER PALLIATIVE THERAPY;
CANCER PATIENT;
COST BENEFIT ANALYSIS;
COST EFFECTIVENESS ANALYSIS;
DRUG INTERACTION;
GERIATRIC PATIENT;
HEALTH CARE COST;
HUMAN;
LETTER;
NEUTROPENIA;
POLYPHARMACY;
POSTOPERATIVE COMPLICATION;
PRIORITY JOURNAL;
PROPHYLAXIS;
RISK ASSESSMENT;
RISK FACTOR;
SEPSIS;
METABOLISM;
METHODOLOGY;
NEOPLASM;
NOTE;
ONCOLOGY;
PALLIATIVE THERAPY;
PRACTICE GUIDELINE;
THEORETICAL MODEL;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
DRUG INTERACTIONS;
HUMANS;
MEDICAL ONCOLOGY;
MODELS, THEORETICAL;
NEOPLASMS;
PALLIATIVE CARE;
POLYPHARMACY;
PRACTICE GUIDELINES AS TOPIC;
|
EID: 77951901716
PISSN: 09237534
EISSN: 15698041
Source Type: Journal
DOI: 10.1093/annonc/mdp539 Document Type: Letter |
Times cited : (5)
|
References (6)
|